Cargando…

Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer

To evaluate the racial and ethnic differences in prevalence of germline pathogenic variants (PVs) and the effect of race and ethnicity on breast cancer (BC) risk among carriers, results of multigene testing of 77 900 women with BC (non-Hispanic White [NHW] = 57 003; Ashkenazi-Jewish = 4798; Black =...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yadav, Siddhartha, LaDuca, Holly, Polley, Eric C, Hu, Chunling, Niguidula, Nancy, Shimelis, Hermela, Lilyquist, Jenna, Na, Jie, Lee, Kun Y, Gutierrez, Stephanie, Yussuf, Amal, Hart, Steven N, Davis, Brigette Tippin, Chao, Elizabeth C, Pesaran, Tina, Goldgar, David E, Dolinsky, Jill S, Couch, Fergus J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633452/ https://www.ncbi.nlm.nih.gov/pubmed/33146377 http://dx.doi.org/10.1093/jnci/djaa167

Ejemplares similares

Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes
por: Hu, Chunling, et al.
Publicado: (2018)

Mutation prevalence tables for hereditary cancer derived from multigene panel testing
por: Hart, Steven N., et al.
Publicado: (2020)

The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort
por: Hu, Chunling, et al.
Publicado: (2020)

Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort
por: Li, Hongyan, et al.
Publicado: (2019)

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
por: Shimelis, Hermela, et al.
Publicado: (2018)

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients
por: LaDuca, Holly, et al.
Publicado: (2019)

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
por: Pritzlaff, Mary, et al.
Publicado: (2016)

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients
por: LaDuca, Holly, et al.
Publicado: (2014)

An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance
por: Iversen, Edwin S., et al.
Publicado: (2022)

Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer
por: Karam, Rachid, et al.
Publicado: (2019)

Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations
por: Horton, Carolyn, et al.
Publicado: (2022)

Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance
por: Richardson, Marcy E., et al.
Publicado: (2021)

False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care
por: Tandy-Connor, Stephany, et al.
Publicado: (2018)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models
por: Hart, Steven N., et al.
Publicado: (2018)

Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
por: Hu, Chunling, et al.
Publicado: (2023)

Diagnosing hereditary cancer predisposition in men with prostate cancer
por: Pritzlaff, Mary, et al.
Publicado: (2020)

Multigene Panel Testing for Hereditary Cancer Risk
por: Grissom, Alyssa A., et al.
Publicado: (2016)

Application of Multigene Panels Testing for Hereditary Cancer Syndromes
por: Bilyalov, Airat, et al.
Publicado: (2022)

Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients
por: ARSLAN ATES, Esra, et al.
Publicado: (2022)

Universal Multi Gene Panel Testing For Individuals With Pheochromocytomas And Paragangliomas
por: Horton, Carolyn, et al.
Publicado: (2021)

The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway
por: Asphaug, Lars, et al.
Publicado: (2019)

Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield
por: Horton, Carolyn, et al.
Publicado: (2022)

Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes
por: Pesaran, T., et al.
Publicado: (2016)

Classification of the canonical splice alteration MUTYH c.934-2A > G is likely benign based on RNA and clinical data
por: Hernandez, Felicia, et al.
Publicado: (2022)

Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception
por: Bychkovsky, Brittany L., et al.
Publicado: (2023)

Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception
por: Bychkovsky, Brittany L., et al.
Publicado: (2023)

Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition
por: Martin-Morales, Lorena, et al.
Publicado: (2018)

Diagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal‐Dominant Hereditary Connective Tissue Disease
por: Capuano, Alessandra, et al.
Publicado: (2015)

Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience
por: Calvello, Mariarosaria, et al.
Publicado: (2023)

Integration of multigene panels for the diagnosis of hereditary retinal disorders using Next Generation Sequencing and bioinformatics approaches
por: Di Resta, Chiara, et al.
Publicado: (2018)

Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
por: Ryu, Jin‐Sun, et al.
Publicado: (2020)

Genetic Variation and the Role of Multigene Panel Testing for Hereditary Breast Cancer: A Single-Institution Experience
por: Lu, Kit, et al.
Publicado: (2021)

Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing
por: Cummings, Shelly, et al.
Publicado: (2023)

Validation of a prostate cancer polygenic risk score
por: Black, Mary H., et al.
Publicado: (2020)

Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients
por: Jones, T, et al.
Publicado: (2019)

Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6
por: Deshmukh, Dhanraj, et al.
Publicado: (2022)

Optimizing the identification of risk‐relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families
por: Coppa, Anna, et al.
Publicado: (2017)

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
por: Eliade, Marie, et al.
Publicado: (2016)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a60jp8jit0p6jr61mg9dakvcns